Novel Keap1-Nrf2 Protein-Protein Interaction Inhibitor UBE-1099 Ameliorates Progressive Phenotype in Alport Syndrome Mouse Model.

Shota KasedaYuya SannomiyaJun HorizonoJun Kuwazuru Mary Ann SuicoSayaka OgiRyoko SasakiHidetoshi SunamotoHirohiko FukiyaHayato NishiyamaMisato KamuraSaki NiinouYuimi KoyamaFutoshi NaraTsuyoshi ShutoKazuhiro OnumaHirofumi Kai

Published in: Kidney360 (2021)

UBE-1099 significantly ameliorates the progressive phenotype in Alport mice. Our results revealed the efficacy of Keap1-Nrf2 PPI inhibitor for glomerulosclerosis and present a potential therapeutic drug for CKD.

Keyphrases

protein protein
mouse model
small molecule
multiple sclerosis
oxidative stress
chronic kidney disease
case report
single cell
adverse drug
adipose tissue
insulin resistance